Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Moderna Inc
(NQ:
MRNA
)
68.02
-1.84 (-2.63%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Moderna Inc
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Moderna Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19
June 10, 2024
Via
ACCESSWIRE
Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine
June 07, 2024
Via
ACCESSWIRE
Meme Stocks Surge Led by ‘Roaring Kitty’ and Social Media Buzz on Reddit (NYSE: RDDT), GME, DYAI, AMC, PRSO, NVAX
June 06, 2024
Via
AB Newswire
Novavax Stock’s Recent Surge and Future Potential
June 06, 2024
Novavax's future hinges on its ability to translate recent stock market momentum into sustained financial performance.
Via
MarketBeat
Topics
Economy
Exposures
COVID-19
Product Safety
Supply Chain
Dyadic International Inc. (NASDAQ: DYAI) Hits New 52-Week High Amidst Golden Cross, Bullish Swing Patterns and Bird Flu Concerns
June 06, 2024
Via
AB Newswire
Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)
May 31, 2024
Via
ACCESSWIRE
Moderna Announces Data to be Presented at 2024 ASCO Annual Meeting
May 22, 2024
Via
ACCESSWIRE
Moderna's Investigational Therapeutic for Methylmalonic Acidemia (mRNA-3705) Selected by U.S. Food & Drug Administration for START Pilot Program
June 06, 2024
Via
ACCESSWIRE
Moderna, Inc. (MRNA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
June 03, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Moderna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in Recurrence-Free Survival & Distant Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stage
June 03, 2024
Via
ACCESSWIRE
Dyadic International Inc. (DYAI): Bird Flu Vaccine Development Amid Rising Pandemic Concerns
May 30, 2024
Via
AB Newswire
Exposures
COVID-19
Moderna to Present at Upcoming Conferences in May/June 2024
May 13, 2024
Via
ACCESSWIRE
Moderna Announces Update on Investigational RSV Vaccine
May 10, 2024
Via
ACCESSWIRE
Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates
May 02, 2024
Via
ACCESSWIRE
Will the Biotech Sector Shift From Lagger to Leader?
May 10, 2024
The biotech sector has experienced a significant rally after bouncing off uptrend support and is now consolidating near major SMAs.
Via
MarketBeat
Topics
ETFs
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024
May 08, 2024
EQNX::TICKER_START (OTCPK:MUSLF),(CSE:MUSL),(NYSE:MRK),(NYSE:PFE),(NASDAQ:MRNA),(NASDAQ:AZN) EQNX::TICKER_END
Via
FinancialNewsMedia
Pfizer Finds a Foothold After a Solid Q1 2024 Earnings Report
May 06, 2024
After a painful two-year selloff, Pfizer shareholders may have finally gained a foothold after the company delivered a solid Q1 2024 earnings report
Via
MarketBeat
Exposures
COVID-19
Moderna and OpenAI Collaborate To Advance mRNA Medicine
April 24, 2024
Via
ACCESSWIRE
Moderna Inc. (NASDAQ: MRNA) Leading the Way in Tuesday Trading Based on Percentage Gain
April 09, 2024
Via
Investor Brand Network
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024
May 08, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Moderna Announces Contract with Brazil to Supply 12.5 million COVID-19 Vaccines as Part of National Vaccination Campaign
April 22, 2024
Via
ACCESSWIRE
Moderna to Present at Upcoming Investor Conferences in March 2024
February 28, 2024
Via
ACCESSWIRE
Moderna Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Updates
February 22, 2024
Via
ACCESSWIRE
Moderna to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
April 17, 2024
Via
ACCESSWIRE
Phase 1/2 Interim Data on Moderna’s mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia, Published in Nature
April 03, 2024
Via
ACCESSWIRE
Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials
March 27, 2024
Via
ACCESSWIRE
Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine
March 26, 2024
Via
ACCESSWIRE
Moderna to Host Fifth Annual Investor Event For Vaccines and Business Updates on March 27, 2024
February 29, 2024
Via
ACCESSWIRE
Novavax’s dispute resolution and upcoming earnings call
February 23, 2024
Novavax navigates legal settlements, earnings expectations, and competition, hoping their protein-based vaccines become a global health game-changer.
Via
MarketBeat
Topics
Earnings
Exposures
COVID-19
Financial
Moderna Chief Executive Officer Stéphane Bancel Elected to National Academy of Engineering
February 06, 2024
Via
ACCESSWIRE
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.